JAGUAR HEALTH, INC. Convertible Preferred Stock, Shares Issued upon Conversion
JAGUAR HEALTH, INC. (JAGX) had Convertible Preferred Stock, Shares Issued upon Conversion of 595 shares as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Stockholders' Equity Note › Class of Stock Disclosures
us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion · last filed 2026-08-19
- 2026-06-30: Convertible Preferred Stock, Shares Issued upon Conversion 595.00 shares.
- 2026-03-31: Convertible Preferred Stock, Shares Issued upon Conversion 596.00 shares.
- 2025-12-31: Convertible Preferred Stock, Shares Issued upon Conversion 56.00K shares; Convertible Preferred Stock, Shares Issued upon Conversion as first filed 1.96M shares.
- 2024-01-15: Convertible Preferred Stock, Shares Issued upon Conversion 1.80K shares; Convertible Preferred Stock, Shares Issued upon Conversion as first filed 44.94K shares.
| Period end | Convertible Preferred Stock, Shares Issued upon Conversion | Convertible Preferred Stock, Shares Issued upon Conversion as first filed |
|---|---|---|
| 2026-06-30 | 595.00 shares 10-Q · filed 2026-08-19 | |
| 2026-03-31 | 596.00 shares 10-Q · filed 2026-05-20 | |
| 2025-12-31 | 56.00K shares 10-Q · filed 2026-08-19 | 1.96M shares 10-K · filed 2026-04-07 |
| 2024-01-15 | 1.80K shares 10-K · filed 2026-04-07 | 44.94K shares 10-Q · filed 2024-08-13 |
| 2019-07-31 | 166.00 shares 10-K · filed 2022-03-11 | 500.00 shares 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |